Vivani Medical, Inc. (VANI) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated July 1, 2026, discloses a material definitive agreement entered into by Vivani Medical, Inc. ("Vivani"). The filing details a proposed merger between Vivani's wholly-owned subsidiary, Cortigent, Inc., and ClearOne, Inc., a Nasdaq-listed company. Additionally, the report references a separate press release issued on July 7, 2026, regarding a collaboration with Novo Nordisk.
Key Financial Metrics and Transaction Terms
The filing does not provide historical revenue, profit, or cash flow metrics for Vivani or Cortigent. Financial details are limited to the terms of the proposed transaction:
- Merger Consideration: Vivani will receive 12,500,000 shares of ClearOne common stock in exchange for all issued and outstanding Cortigent equity securities.
- Financing Requirement: As a condition to closing, ClearOne must raise between $10,000,000 and $15,000,000 via a Form S-1 registration.
- Financing Structure: The raise will consist of 2,500,000 to 5,000,000 units, each comprising one share of ClearOne common stock and one warrant to purchase one share at an exercise price of $10.00.
- Breakup Fee: A termination fee of up to $250,000 (capped at 125% of direct third-party expenses) may be payable upon termination under specified circumstances.
Material Changes and Governance
Upon the effective time of the merger, the following structural changes are anticipated:
- Corporate Structure: Cortigent will merge into a ClearOne subsidiary and become a wholly-owned subsidiary of ClearOne.
- Board Composition: The combined company's Board of Directors will consist of five members: four designated by Vivani (including the Chairperson) and one designated by pre-closing ClearOne stockholders.
- Stockholder Support: ClearOne shareholders holding at least 50.1% of common stock have agreed to vote in favor of the transaction.
- Lock-Up Agreements: Vivani agreed to lock-up restrictions on the consideration shares: 50% for one year and 50% for two years post-closing.
Guidance, Risks, and Unusual Items
Conditions to Closing: The transaction is contingent upon stockholder approvals, regulatory compliance, continuous Nasdaq listing for ClearOne, and the successful consummation of the $10M-$15M financing.
Termination Rights: Either party may terminate if the merger is not completed by December 28, 2026 (180 days post-signing), subject to extensions.
Risks and Uncertainties: Management highlights significant risks including the failure to secure financing, inability to obtain stockholder approval, potential delisting from Nasdaq, and market fluctuations affecting the value of the fixed share consideration. The filing includes extensive forward-looking statements regarding the combined company's future operations and cash runway, noting that actual results may differ materially.
Other Information: On July 7, 2026, Vivani announced an agreement with Novo Nordisk to evaluate NPM-139, a semaglutide drug implant utilizing Vivani's NanoPortal platform for chronic weight management.
Investor Verification Checklist
- Verify the status of the Form S-1 registration statement filed by ClearOne to ensure the required $10M-$15M financing is secured.
- Monitor the stockholder vote results for both Cortigent (via Vivani) and ClearOne, as approval is a mandatory closing condition.
- Confirm the Nasdaq listing status of ClearOne and the approval for the new ticker symbol "CRGT" for the combined entity.
- Review the full text of the Merger Agreement (Exhibit 2.1) for specific representations, warranties, and indemnification clauses not summarized here.
- Assess the impact of the lock-up agreements on the liquidity of Vivani's consideration shares post-closing.